Professor Emma Culver, Consultant Hepatologist, John Radcliffe Hospital, Oxford
Kath Houghton, Autoimmune Liver Nurse, Freeman Hospital, Newcastle
This promotional webinar has been developed, organised and funded by ADVANZ PHARMA and is intended for UK healthcare professionals only.
OCALIVA®?(obeticholic acid) is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. OCALIVA® has a conditional approval in PBC. For prescribing information, click here.
Adverse events should be reported. Reporting forms and information for the UK can be found at https://yellowcard.mhra.gov.uk/ and also report using the Yellow Card app. The app is available to download from the Apple App Store, or Google Play Store and you can use your Yellow Card website account details on the app to report. Adverse events should also be reported to ADVANZ PHARMA Medical Information via telephone on +44 (0) 208 588 9131 or via e-mail at medicalinformation@advanzpharma.com
